KDM6B过表达与TET2缺陷在慢性粒单核细胞白血病发病中的协同作用
在初治慢性粒单核细胞白血病(CMML)患者中,同时携带TET2突变和KDM6B过表达者占队列18%、占TET2突变患者的42%。双病变小鼠模型表现出比单一Tet2缺陷或KDM6B过表达更明显的CMML样表型。KDM6B抑制剂可降低双病变小鼠的骨髓再增殖活性及移植了TET2突变CMML患者骨髓造血干祖细胞的小鼠的肿瘤负荷。
要点
- TET2突变合并KDM6B过表达占CMML队列18%、占TET2突变者42%。
- 双病变小鼠CMML样表型较单一病变更明显,包括单核细胞增多、贫血、脾大。
- KDM6B抑制剂降低双病变小鼠骨髓再增殖活性及人源移植小鼠肿瘤负荷。
核心结论
- TET2缺陷与KDM6B过表达在CMML发病中协同作用,KDM6B可能成为该病的潜在治疗靶点。
研究设计与样本
- 对初治CMML患者进行基因组和转录组分析,并构建同时携带Tet2缺陷和KDM6B过表达的双病变小鼠模型。
主要发现
- 同时携带TET2突变和KDM6B过表达的患者占队列18%、占TET2突变患者的42%。
- 双病变小鼠较单纯Tet2缺陷或KDM6B过表达小鼠表现出更明显的CMML样表型,包括单核细胞增多、贫血、脾大及骨髓造血干祖细胞频率和再增殖活性增加。
- 双病变小鼠存在显著转录改变,与促炎信号激活和维持基因组稳定信号抑制相关。
- KDM6B抑制剂降低双病变小鼠的骨髓再增殖活性,并降低移植了TET2突变CMML患者骨髓造血干祖细胞的小鼠的肿瘤负荷。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Loss-of-function TET2 mutations are recurrent somatic lesions in chronic myelomonocytic leukemia (CMML). KDM6B encodes a histone demethylase involved in innate immune regulation that is overexpressed in CMML. We conducted genomic and transcriptomic analyses in treatment naïve CMML patients and observed that the patients carrying both TET2 mutations and KDM6B overexpression constituted 18% of the cohort and 42% of patients with TET2 mutations. We therefore hypothesized that KDM6B overexpression cooperated with TET2 deficiency in CMML pathogenesis. We developed a double-lesion mouse model with both aberrations, and discovered that the mice exhibited a more prominent CMML-like phenotype than mice with either Tet2 deficiency or KDM6B overexpression alone. The phenotype includes monocytosis, anemia, splenomegaly, and increased frequencies and repopulating activity of bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). Significant transcriptional alterations were identified in double-lesion mice, which were associated with activation of proinflammatory signals and repression of signals maintaining genome stability. Finally, KDM6B inhibitor reduced BM repopulating activity of double-lesion mice and tumor burden in mice transplanted with BM-HSPCs from CMML patients with TET2 mutations. These data indicate that TET2 deficiency and KDM6B overexpression cooperate in CMML pathogenesis of and that KDM6B could serve as a potential therapeutic target in this disease.
引用
- Wei Y, Kanagal-Shamanna R, Zheng H, et al. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022. PMID: 35697791. doi:10.1038/s41375-022-01605-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。